RARE Daily

Kriya Raises $270 Million to Advance Fully Integrated Gene Therapy Engine

May 16, 2022

Kriya Therapeutics, a fully integrated gene therapy company pioneering novel technologies and therapeutics, raised $270 million in a series C financing round to advance its pipeline and continued scaling of its engineering, manufacturing, and computational platforms.

Photo: Shankar Ramaswamy, co-founder and CEO of Kriya

Patient Square Capital led the financing with participation from Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT, Transhuman Capital, and other undisclosed investors.

Kriya has established an ecosystem for delivering best-in-class technologies and medicines in gene therapy, with core business units in technology, manufacturing, R&D, and therapeutics. By leveraging its proprietary computational platform, in-house manufacturing infrastructure, and rational design toolkit, the company is positioned to bring potentially transformative gene therapies to a broad range of diseases, while improving speed to market and reducing cost.

Kriya’s product pipeline addresses diseases of high unmet need with therapeutic area divisions in ophthalmology, oncology, rare disease, and chronic disease, each led by industry veterans with a track record of advancing products from concept through commercialization.

“We believe gene therapy has the potential to redefine medicine over the next decade. However, the field has been constrained by technological and operational challenges that make it difficult and expensive to deliver new products,” said Shankar Ramaswamy, co-founder and CEO of Kriya. “Kriya was founded to address the primary problems limiting the field, and I am proud of the progress we have made to date. This financing will support our continued growth as we advance our diverse pipeline into the clinic and further scale our core platforms, to achieve our ultimate vision of expanding the reach and unlocking the full potential of gene therapy as a modality.”

In recent months, Kriya has achieved several milestones across key parts of its business. The company significantly expanded its pipeline through its internal R&D efforts, as well as through acquisitions and partnerships. In addition, Kriya operationalized its state-of-the-art, scalable GMP manufacturing infrastructure in Research Triangle Park, North Carolina to support in-house production from early through late phase development. This infrastructure also empowers the development and implementation of novel technologies and processes that enable consistent, large-scale manufacturing. Kriya has also scaled SIRVE, its machine learning-enabled technology and cloud computing architecture, to support the integration of large datasets generated by the company’s high throughput screening, next generation sequencing, and algorithmic data mining platforms.

Author: Rare Daily Staff

Stay Connected

Sign up for updates straight to your inbox.